PD-1‑resistant murine esophageal squamous cell carcinoma cell line: establishment and multi-omics

Background and clinical need

Immunotherapy, particularly immune checkpoint blockade, has changed the therapeutic landscape for esophageal squamous cell carcinoma (ESCC). Despite this progress, clinical application remains constrained by generally low objective response rates and the frequent emergence of acquired resistance. The limited effectiveness for many patients highlights the need to better understand mechanisms of primary and secondary resistance to PD-1 pathway inhibitors.

Preclinical research into resistance mechanisms and strategies to overcome them depends on models that faithfully reproduce not only tumor cell–intrinsic biology but also the tumor immune microenvironment and clinically relevant resistance phenotypes. The absence of such models for ESCC has been identified as a barrier to translational progress.

Study aim and model established

According to the PubMed record (Biochem Biophys Res Commun. 2026; PMID: 42259198), the investigators set out to address this gap by establishing a PD-1-resistant murine ESCC cell line and performing multi-omics characterization. The truncated abstract indicates the central accomplishment—generation of a resistant murine cell line and subsequent omics profiling—but the available source text ends early and does not include the full description of the work.

Methods reported in source

The excerpt of the PubMed abstract provided for this request does not include methodological details. Specifically, the following items were not reported in the supplied text:

• How the PD-1 resistance phenotype was generated or selected (for example, serial in vivo exposure, genetic manipulation, or other approaches).
• Whether the model is an isolated cell line, a syngeneic tumor line, or maintained in immunocompetent mice to preserve immune contexture.
• The specific multi-omics platforms used (for example, whole-exome sequencing, RNA-seq, proteomics, single-cell assays, epigenomics) and experimental workflows.
• Validation methods for resistance (tumor growth under PD-1 blockade, immune infiltration assays, functional immune assays).

Because these experimental and technical details are not present in the abstract fragment available here, they cannot be restated or inferred from this source.

Multi-omics characterization reported in source

The abstract specifies that a multi-omics characterization was performed on the established PD-1-resistant murine ESCC cell line. However, the supplied PubMed content does not enumerate the omics layers analyzed, the major molecular findings, or the analytic approaches. Therefore, information such as differentially expressed genes, mutational signatures, proteomic changes, immune cell composition, pathway alterations, or candidate resistance mechanisms was not reported in the excerpt.

Results and specific findings

The PubMed record accessed for this rewrite is truncated and does not include results. The following categories of key data are not available in the provided source text and therefore are not reported here:

• Experimental evidence demonstrating PD-1 resistance in vitro or in vivo.
• Molecular alterations or pathways implicated by the multi-omics profiling.
• Any candidate biomarkers of resistance or potential therapeutic vulnerabilities identified.
• Comparative data versus PD-1–sensitive ESCC models, if performed.

Because the abstract truncation prevents access to these findings, no numerical results, statistical outcomes, or specific molecular conclusions can be supplied from this source.

Conclusions and implications

From the portion of the abstract that is present, the primary deliverable of the study is the generation of a preclinical PD-1-resistant ESCC model accompanied by multi-omics profiling. The truncated record suggests the study aims to provide a tool for investigation of immune checkpoint resistance in ESCC, but the full text would be required to determine the authors’ explicit conclusions, proposed mechanisms of resistance, or suggested translational applications.

In general terms, establishment of a well-characterized PD-1–resistant murine ESCC model could support:

• Mechanistic studies dissecting tumor-intrinsic and microenvironmental contributors to immune evasion.
• Preclinical testing of combination regimens designed to overcome checkpoint blockade resistance.
• Identification of candidate biomarkers for resistance or response monitoring.

However, these broader implications are contextual and are not detailed in the truncated PubMed abstract provided here.

Publication and citation details

This work is listed as: Yi Xu et al., Biochemical and Biophysical Research Communications. 2026. PubMed PMID: 42259198. DOI: 10.1016/j.bbrc.2026.154109. The PubMed record available for this request contains only a partial abstract that ends after the phrase “Here, we established,” and thus does not report methods, results, or detailed conclusions in the supplied text.

Note on source limitations

All statements in this summary and rewritten article are derived solely from the PubMed page content supplied with this request. The supplied abstract text was truncated; therefore, methodological specifics, quantitative results, detailed multi-omics findings, and the authors’ full conclusions were not available and are not reported here. To obtain complete experimental details and validated findings, consult the full text via the DOI or journal link.